🧫
Gap26 treatment in UAC rat model of TMJOA
active
experiment
Created: 2026-04-10T22:49:52
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-a87f6346-8704-4835-83d3-9cbcb4f7c196
🧫 Experiment Protocol
ValidationTemporomandibular joint osteoarthritisCx43UAC rats treated with Gap26 inhibitorproposed
A therapeutic intervention study using Gap26 Connexin 43 inhibitor in the unilateral anterior crossbite rat model to evaluate its potential as a treatment for TMJOA. This experiment tested whether pharmacological inhibition of Cx43 could prevent or ameliorate the degenerative changes, Wnt/β-catenin pathway activation, and cartilage degradation observed in the UAC model, providing evidence for Cx43 as a potential therapeutic target.
PRIMARY OUTCOME
Mitigation of degenerative changes and suppressed Wnt signaling
EXPECTED OUTCOMES
Gap26 treatment would reduce TMJ degeneration and suppress pathological signaling pathways
SUCCESS CRITERIA
Demonstration of reduced cartilage degeneration, decreased Cx43 activity, and suppressed Wnt/β-catenin signaling compared to untreated UAC controls
PROTOCOL
Administration of Gap26 inhibitor to UAC rats followed by assessment of TMJ degeneration, Cx43 activity, and Wnt/β-catenin signaling compared to untreated controls
Source: PMID 41757775 ↗
🧫 Experiment Extras
PATHWAY
Wnt/β-catenin signaling
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.